Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
Copyright © 2022 Massachusetts Medical Society..
BACKGROUND: Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan-human-coronavirus activity in vitro.
METHODS: We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated.
RESULTS: A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo.
CONCLUSIONS: Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.).
| Errataetall: |
CommentIn: Nature. 2022 Apr;604(7906):412-413. - PMID 35379975 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:386 |
|---|---|
| Enthalten in: |
The New England journal of medicine - 386(2022), 15 vom: 14. Apr., Seite 1397-1408 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hammond, Jennifer [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2022 Date Revised 16.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT04960202 CommentIn: Nature. 2022 Apr;604(7906):412-413. - PMID 35379975 Citation Status MEDLINE |
|---|
| doi: |
10.1056/NEJMoa2118542 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM337039933 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM337039933 | ||
| 003 | DE-627 | ||
| 005 | 20240416232146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMoa2118542 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM337039933 | ||
| 035 | |a (NLM)35172054 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hammond, Jennifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2022 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04960202 | ||
| 500 | |a CommentIn: Nature. 2022 Apr;604(7906):412-413. - PMID 35379975 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Massachusetts Medical Society. | ||
| 520 | |a BACKGROUND: Nirmatrelvir is an orally administered severe acute respiratory syndrome coronavirus 2 main protease (Mpro) inhibitor with potent pan-human-coronavirus activity in vitro | ||
| 520 | |a METHODS: We conducted a phase 2-3 double-blind, randomized, controlled trial in which symptomatic, unvaccinated, nonhospitalized adults at high risk for progression to severe coronavirus disease 2019 (Covid-19) were assigned in a 1:1 ratio to receive either 300 mg of nirmatrelvir plus 100 mg of ritonavir (a pharmacokinetic enhancer) or placebo every 12 hours for 5 days. Covid-19-related hospitalization or death from any cause through day 28, viral load, and safety were evaluated | ||
| 520 | |a RESULTS: A total of 2246 patients underwent randomization; 1120 patients received nirmatrelvir plus ritonavir (nirmatrelvir group) and 1126 received placebo (placebo group). In the planned interim analysis of patients treated within 3 days after symptom onset (modified intention-to treat population, comprising 774 of the 1361 patients in the full analysis population), the incidence of Covid-19-related hospitalization or death by day 28 was lower in the nirmatrelvir group than in the placebo group by 6.32 percentage points (95% confidence interval [CI], -9.04 to -3.59; P<0.001; relative risk reduction, 89.1%); the incidence was 0.77% (3 of 389 patients) in the nirmatrelvir group, with 0 deaths, as compared with 7.01% (27 of 385 patients) in the placebo group, with 7 deaths. Efficacy was maintained in the final analysis involving the 1379 patients in the modified intention-to-treat population, with a difference of -5.81 percentage points (95% CI, -7.78 to -3.84; P<0.001; relative risk reduction, 88.9%). All 13 deaths occurred in the placebo group. The viral load was lower with nirmatrelvir plus ritonavir than with placebo at day 5 of treatment, with an adjusted mean difference of -0.868 log10 copies per milliliter when treatment was initiated within 3 days after the onset of symptoms. The incidence of adverse events that emerged during the treatment period was similar in the two groups (any adverse event, 22.6% with nirmatrelvir plus ritonavir vs. 23.9% with placebo; serious adverse events, 1.6% vs. 6.6%; and adverse events leading to discontinuation of the drugs or placebo, 2.1% vs. 4.2%). Dysgeusia (5.6% vs. 0.3%) and diarrhea (3.1% vs. 1.6%) occurred more frequently with nirmatrelvir plus ritonavir than with placebo | ||
| 520 | |a CONCLUSIONS: Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns. (Supported by Pfizer; ClinicalTrials.gov number, NCT04960202.) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Lactams |2 NLM | |
| 650 | 7 | |a Leucine |2 NLM | |
| 650 | 7 | |a GMW67QNF9C |2 NLM | |
| 650 | 7 | |a nirmatrelvir |2 NLM | |
| 650 | 7 | |a 7R9A5P7H32 |2 NLM | |
| 650 | 7 | |a nirmatrelvir and ritonavir drug combination |2 NLM | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a Proline |2 NLM | |
| 650 | 7 | |a 9DLQ4CIU6V |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Viral Protease Inhibitors |2 NLM | |
| 700 | 1 | |a Leister-Tebbe, Heidi |e verfasserin |4 aut | |
| 700 | 1 | |a Gardner, Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Abreu, Paula |e verfasserin |4 aut | |
| 700 | 1 | |a Bao, Weihang |e verfasserin |4 aut | |
| 700 | 1 | |a Wisemandle, Wayne |e verfasserin |4 aut | |
| 700 | 1 | |a Baniecki, MaryLynn |e verfasserin |4 aut | |
| 700 | 1 | |a Hendrick, Victoria M |e verfasserin |4 aut | |
| 700 | 1 | |a Damle, Bharat |e verfasserin |4 aut | |
| 700 | 1 | |a Simón-Campos, Abraham |e verfasserin |4 aut | |
| 700 | 1 | |a Pypstra, Rienk |e verfasserin |4 aut | |
| 700 | 1 | |a Rusnak, James M |e verfasserin |4 aut | |
| 700 | 0 | |a EPIC-HR Investigators |e verfasserin |4 aut | |
| 700 | 1 | |a Aazami, Hessam |e investigator |4 oth | |
| 700 | 1 | |a Abinante, Matthew |e investigator |4 oth | |
| 700 | 1 | |a Abrishamian, Luis |e investigator |4 oth | |
| 700 | 1 | |a Aguirre Rivero, Rafael |e investigator |4 oth | |
| 700 | 1 | |a Akhan, Sila |e investigator |4 oth | |
| 700 | 1 | |a Aksoy, Firdevs |e investigator |4 oth | |
| 700 | 1 | |a Barwani, Aalia Al |e investigator |4 oth | |
| 700 | 1 | |a Amishima, Masaru |e investigator |4 oth | |
| 700 | 1 | |a Anderson, Duane |e investigator |4 oth | |
| 700 | 1 | |a Antonov, Chavdar |e investigator |4 oth | |
| 700 | 1 | |a Avihingsanon, Anchalee |e investigator |4 oth | |
| 700 | 1 | |a Ayesu, Kwabena |e investigator |4 oth | |
| 700 | 1 | |a Ayyappath, Paramez |e investigator |4 oth | |
| 700 | 1 | |a Balik, Ismail |e investigator |4 oth | |
| 700 | 1 | |a Barrat Hernandez, Alejandro |e investigator |4 oth | |
| 700 | 1 | |a Batista de Moura Xavier de Moraes, Joao |e investigator |4 oth | |
| 700 | 1 | |a Benitez, Omar |e investigator |4 oth | |
| 700 | 1 | |a Benitez, Wilfrido |e investigator |4 oth | |
| 700 | 1 | |a Berenfus, Vadym |e investigator |4 oth | |
| 700 | 1 | |a Boghara, Haresh |e investigator |4 oth | |
| 700 | 1 | |a Brabham, David |e investigator |4 oth | |
| 700 | 1 | |a Buchvarov, Mladen |e investigator |4 oth | |
| 700 | 1 | |a Budhraja, Akshay |e investigator |4 oth | |
| 700 | 1 | |a Buendía Magaña, Ruben |e investigator |4 oth | |
| 700 | 1 | |a Buendia Suárez, Isabel |e investigator |4 oth | |
| 700 | 1 | |a Cannon, Kevin |e investigator |4 oth | |
| 700 | 1 | |a Capote, Eddy |e investigator |4 oth | |
| 700 | 1 | |a Chaudhari, Piyush |e investigator |4 oth | |
| 700 | 1 | |a Chua, Hock Hin |e investigator |4 oth | |
| 700 | 1 | |a Chusri, Sarunyou |e investigator |4 oth | |
| 700 | 1 | |a Cortes, Anais |e investigator |4 oth | |
| 700 | 1 | |a Crawford, Paul |e investigator |4 oth | |
| 700 | 1 | |a Calleiro, Maria Curbelo |e investigator |4 oth | |
| 700 | 1 | |a Czerech, Ewa |e investigator |4 oth | |
| 700 | 1 | |a Dange, Amol |e investigator |4 oth | |
| 700 | 1 | |a De La Vega, Dagoberto |e investigator |4 oth | |
| 700 | 1 | |a Del Carpio Orantes, Luis |e investigator |4 oth | |
| 700 | 1 | |a Deno, Yohanna |e investigator |4 oth | |
| 700 | 1 | |a Desantis, Kimberly |e investigator |4 oth | |
| 700 | 1 | |a Diaz, Jorge |e investigator |4 oth | |
| 700 | 1 | |a Dobreva, Vanya |e investigator |4 oth | |
| 700 | 1 | |a Dombi, Attila |e investigator |4 oth | |
| 700 | 1 | |a Drasnar, Tomas |e investigator |4 oth | |
| 700 | 1 | |a Duardo-Guerra, Yamirka |e investigator |4 oth | |
| 700 | 1 | |a Dukes, Carl |e investigator |4 oth | |
| 700 | 1 | |a Fakih, Faisal |e investigator |4 oth | |
| 700 | 1 | |a Fam, Tem Lom |e investigator |4 oth | |
| 700 | 1 | |a Fatakia, Adil |e investigator |4 oth | |
| 700 | 1 | |a Fernandez-Miro, Humberto |e investigator |4 oth | |
| 700 | 1 | |a Flores Figueroa, Jose |e investigator |4 oth | |
| 700 | 1 | |a Fouche, Leon |e investigator |4 oth | |
| 700 | 1 | |a Galitz, Lawrence |e investigator |4 oth | |
| 700 | 1 | |a Galvez, Oscar |e investigator |4 oth | |
| 700 | 1 | |a Garcia, Lazaro |e investigator |4 oth | |
| 700 | 1 | |a Gavrylov, Anatoliy |e investigator |4 oth | |
| 700 | 1 | |a Georgieva, Stela |e investigator |4 oth | |
| 700 | 1 | |a Georgiev, Emil |e investigator |4 oth | |
| 700 | 1 | |a Giriappa, Balachandra |e investigator |4 oth | |
| 700 | 1 | |a Gudzheva, Rumyana Gavrailova |e investigator |4 oth | |
| 700 | 1 | |a Gunduz, Alper |e investigator |4 oth | |
| 700 | 1 | |a Gunluoglu, Gulsah |e investigator |4 oth | |
| 700 | 1 | |a Haracherova, Kameliya |e investigator |4 oth | |
| 700 | 1 | |a Harcsa, Eleonora |e investigator |4 oth | |
| 700 | 1 | |a Haytova, Nezabravka |e investigator |4 oth | |
| 700 | 1 | |a Hernández Pichardo, Joselito |e investigator |4 oth | |
| 700 | 1 | |a Hernandez, Humberto |e investigator |4 oth | |
| 700 | 1 | |a Hernandez, Manuel |e investigator |4 oth | |
| 700 | 1 | |a Hirai, Yuji |e investigator |4 oth | |
| 700 | 1 | |a Hoosen, Farzana |e investigator |4 oth | |
| 700 | 1 | |a Hristova, Iskra |e investigator |4 oth | |
| 700 | 1 | |a Hristovski, Boyan |e investigator |4 oth | |
| 700 | 1 | |a Hussen, Nazreen |e investigator |4 oth | |
| 700 | 1 | |a Igbinadolor, Awawu |e investigator |4 oth | |
| 700 | 1 | |a Inan, Dilara |e investigator |4 oth | |
| 700 | 1 | |a Issa, Husam |e investigator |4 oth | |
| 700 | 1 | |a Jain, Manish |e investigator |4 oth | |
| 700 | 1 | |a Jeudy, Wilner |e investigator |4 oth | |
| 700 | 1 | |a Jimenez, Mario |e investigator |4 oth | |
| 700 | 1 | |a Jindal, Atul |e investigator |4 oth | |
| 700 | 1 | |a Kalfov, Veselin |e investigator |4 oth | |
| 700 | 1 | |a Kandemir, Fatma |e investigator |4 oth | |
| 700 | 1 | |a Kang, Seung Ji |e investigator |4 oth | |
| 700 | 1 | |a Karabay, Oguz |e investigator |4 oth | |
| 700 | 1 | |a Karaoglan, Ilkay |e investigator |4 oth | |
| 700 | 1 | |a Karpenko, Olena |e investigator |4 oth | |
| 700 | 1 | |a Khandelwal, Vipul |e investigator |4 oth | |
| 700 | 1 | |a Kim, Jin Yong |e investigator |4 oth | |
| 700 | 1 | |a Kim, Kenneth |e investigator |4 oth | |
| 700 | 1 | |a Kireieva, Tetiana |e investigator |4 oth | |
| 700 | 1 | |a Kireyev, Igor |e investigator |4 oth | |
| 700 | 1 | |a Kirov, Mihail |e investigator |4 oth | |
| 700 | 1 | |a Kobrynska, Olena |e investigator |4 oth | |
| 700 | 1 | |a Kochar, Sanjay |e investigator |4 oth | |
| 700 | 1 | |a Kohli, Anita |e investigator |4 oth | |
| 700 | 1 | |a Koksal, Iftihar |e investigator |4 oth | |
| 700 | 1 | |a Kolar, Jan |e investigator |4 oth | |
| 700 | 1 | |a Komitov, Iliyan |e investigator |4 oth | |
| 700 | 1 | |a Kosinski, Joseph |e investigator |4 oth | |
| 700 | 1 | |a Koval, Tetiana |e investigator |4 oth | |
| 700 | 1 | |a Kowalczyk, John |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d 1945 |g 386(2022), 15 vom: 14. Apr., Seite 1397-1408 |w (DE-627)NLM000008184 |x 1533-4406 |7 nnns |
| 773 | 1 | 8 | |g volume:386 |g year:2022 |g number:15 |g day:14 |g month:04 |g pages:1397-1408 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMoa2118542 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 386 |j 2022 |e 15 |b 14 |c 04 |h 1397-1408 | ||